Epstein–Barr Virus Primary Infection Complicated by Hemophagocytic Lymphohistiocytosis and Plasmablastic Lymphoma in a HIV-Negative Patient

<div>Epstein–Barr virus (EBV) viremia through days of admission. R = Rituximab administration at 375 mg/m<sup>2</sup>.</div>

Case Reports in Hematology

fig1

Figure 1

Figure 1: Epstein–Barr Virus Primary Infection Complicated by Hemophagocytic Lymphohistiocytosis and Plasmablastic Lymphoma in a HIV-Negative Patient 

Figure 1 | Epstein–Barr Virus Primary Infection Complicated by Hemophagocytic Lymphohistiocytosis and Plasmablastic Lymphoma in a HIV-Negative Patient 